Pfizer AGM: Shareholders Reject Independent Chair Proposal as Bourla Touts 2025 Gains and Pipeline

Pfizer (NYSE:PFE) used its 2026 annual meeting of shareholders to highlight recent operational performance, outline strategic ...
AOL

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...
PharmExec

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Hosted on MSN

Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition

・Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...

Pfizer’s top strategy executive is leaving the company

Pfizer (PFE) stock is in focus as executive Andrew Baum, who joined the company in 2024 as the Chief Strategy and Innovation ...
Fierce Pharma

Pfizer's strategy head Andrew Baum to step down following brief tenure: reports

Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...